Melinta Therapeutics (NASDAQ:MLNT) is scheduled to be announcing its earnings results before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.
Melinta Therapeutics (NASDAQ:MLNT) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($2.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.72) by $0.38. The business had revenue of $14.08 million during the quarter, compared to the consensus estimate of $16.83 million. Melinta Therapeutics had a negative net margin of 161.27% and a negative return on equity of 61.13%. On average, analysts expect Melinta Therapeutics to post $-10 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Shares of NASDAQ:MLNT opened at $3.85 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.06 and a debt-to-equity ratio of 0.87. The stock has a market cap of $43.82 million, a P/E ratio of -0.22 and a beta of 4.31. Melinta Therapeutics has a 52 week low of $1.62 and a 52 week high of $28.25. The company has a 50 day moving average price of $4.97.
About Melinta Therapeutics
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.
Read More: Cost of equity and a company’s balance sheet
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.